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Abstract: 
 
Mesoporous silica nanoparticles (MSNs) are exceptionally promising drug carriers for 
controlled drug delivery systems because their morphology, pore structure, pore volume and 
pore size can be well tailored to obtain certain drug release profiles. Moreover, they possess 
the ability to specifically transport and deliver anti-cancer drugs when targeting molecules are 
properly grafted onto their surface. MSNs based drug delivery systems have the potential to 
revolutionize cancer therapy. This review provides a comprehensive overview of the 
fabrication, modification of MSNs and their applications in tumour-targeted delivery. In 
addition, the characterization and analysis of MSNs with computer aided strategies were 
described. The existing issues and future prospective concerning the applications of MSNs as 
drug carriers for controlled drug delivery systems were discussed.  
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1. Introduction 
The synthesis and application of mesoporous silica nanoparticles (MSN) have attracted great 
attention in the last two decades since the first ordered mesoporous silica molecular sieves (the 
type of MCM-41) were synthesized by Kresge et al. [1] in 1992. The tunability of their structure 
including the particle size, pore diameter, and morphology, and the modification and 
functionalization of surface properties are drawing increasing attention for the purpose of their 
applications in pharmaceutical [2], optics [3], environmental protection [4] and catalysis [5]. 
Particularly, as their controllable mesopores (channels) are able to encapsulate pharmaceutical 
cargoes, the MSNs are exploited to be used as carriers for drug delivery systems.  
 
With the availability of well-established techniques for surface functionalization, MSNs 
possessing biocompatibility [6] can be selectively modified for specific targeting. MSNs based 
targeted drug delivery systems were proved to be effective and efficient in killing targeted cell 
populations. By integrating targeting ligands on the external surface, MSNs can enter and 
release drugs into cancer cells precisely. In addition, MSNs possess the capacity to level off the 
drug concentration at the targeted area as the drug molecules are released from the ordered 
pores or channels of MSNs by a tunable diffusion. When MSNs are functionalized with 
gatekeepers, burst-release can be effectively prevented, which reduces the dosage and prevents 
side effects. Furthermore, the large pore volume and large surface areas lead to a higher drug 
loading [7]. Recent studies have demonstrated examples of MSN as a vehicle for successful 
intracellular delivery of otherwise poorly soluble or membrane impermeable agents to targeted 
cells [8].  
 
This review summarizes the key recent developments in the preparation, functionalization and 
characterization of MSNs for smart delivery, including fabrication mechanism, modifications 
for targeted and controlled release, accumulation and internalization in cancer cells, 
calculations and models for MSNs’ characterization. This would provide insights into the role 
of MSNs in the development of nanomedicine. 
 
  
2. Fabrication of MSNs as nanocarriers  
 
2.1 Formation mechanism of MSNs 
 
There are three key components in the synthesis of MSNs, namely surfactant templates, silica 
precursors and catalysts. Specifically, the surfactant templates form micelles that evolve 
mesoporous structure; the silica precursors forms the silica framework outside the micelles; 
and the catalysts (bases or acids) accelerate the hydrolysis and condensation of silica precursor. 
The growth mechanism of MSNs has intimate relation to these factors. 
 
The meso-structure is formed after organic surfactants that act as templates are removed [9-
11]. A representative synthesis procedure of MCM-41 is shown in Figure 1. The surfactant 
micelles are first formed in an aqueous solution before the hydrolysed silica source is absorbed 
on to the micelle surface. MSNs are formed after condensation of silica source and removal of 
template in mesopores. Experimental conditions, such as the type and concentration of 
surfactants, system temperature, reaction time and stirring speed, have an impact during the 
formation of a micelle [12], controlling the pore and particle sizes [13]. An ordered structure 
of silica shell is then established, the organic templates are eliminated and mesoporous particles 
are finally obtained. Several general methodologies have been carried out during this process, 
such as dissolution [14], dialysis [15], and calcination [16]. Nevertheless, with the 
understanding of the effects of experimental conditions on the mesostructure formation, ideal 
MSNs can be obtained to fulfil the requirements for drug delivery system. 
 
 
 
Figure 1 Possible mechanistic pathways for the formation of MCM-41: (1) liquid crystal phase 
initiated and (2) silicate anion initiated [17]. 
 2.2 Architectural features of MSNs 
 
During the MSN synthesis process, the silicate polymerization directed by templates can be 
controlled in order to design different architectural features [18]. The morphology of MSNs 
can be controlled in different ways, including varying templates, controlling the synthesis pH, 
and choosing additives to control the magnitude of the interactions between the growing silica 
polymer and the assembled templates. Moreover, the control of the rates of the silica source 
hydrolysis and condensation is important to attain certain architectural features of MSNs. 
Sphere, rod, shuttle and lamel are the main structures of MSNs (Figure 2).  
 
 
 
Figure 2 Different particle morphologies of MSNs: (a) rod, (b) sphere, (c) lamel, (d) shuttles, 
(e) core-shell and (d) hollow particles [7, 19]. 
 
Among these MSNs, it is important to choose the right one that can achieve the expected 
functions. For drug delivery, it was reported that the nanospheres exhibited a higher efficiency 
of cell internalization when compared with nanorods. This is based on the positive relationship 
between the particle surface areas and the speed of cell membrane enclosing a particle [20, 21]. 
Moreover, with the development of nanomedicine, demands for nanoplatforms with specific 
performance such as large drug loading gradually increase. To meet such new requirements, 
more and more new methods are under investigation for developing new drug carriers. Hollow 
MSNs (HMSNs) have been studied as a new-generation drug platform for delivery systems 
owning to their extraordinarily high loading capacity. Li and co-workers [22] exploited 
HMSNs as drug carriers to increase the capacity of storing aspirin.  
 
2.3 Synthesis of hollow MSNs 
 
The formation of meso-structure materials is usually attained by the synthesis of liquid-crystal-
like arrays consisting of precursors and templating agents, typically an amphiphilic organic 
surfactant [13] at low-temperature. For hollow MSN, the synthesis is usually achieved by using 
a dual template method. More specifically, a hard or soft template (cave template) which is 
used for the generation of the interior cave is dispersed in a neutral or charged surfactant (pore 
template). Then pore template micelles are formed around the surface of the cave templating 
agents. After that, silica matrix coating on the core template is generated by adding silica source 
agents. Finally, both core and cave templates and pore template micelles are removed by 
thermal calcination or solvent extraction to obtain hollow MSNs with hollow interiors and 
mesoporous shells [23]. 
 
Soft-templating and hard-templating are typical methods to synthesise HMSNs, where 
different core templates are utilized for the creation of the hollow cavities [24]. Soft-templating 
method refers to using surfactants as cave templates to build a hollow interior cave after the 
removal of surfactants. For example, Feng and co-workers [25] synthesized hollow MSNs 
through the aggregation of micelles. In their work, (-)-N-dodecyl-N-methylephedrinium 
bromide (DMEB) was employed as a cave and pore template and carboxyethylsilanetriol 
sodium salt (CSS) was used to stabilize the DMEB micelles. Importantly, the particle size and 
mesoporous shell thickness could be changed by altering the pH values during the synthesis 
possess (Figure 3). It has been suggested that DMEB, CSS and pH values determine the 
morphology of hollow MSNs. Other surfactants using for hollow MSNs fabrication through 
soft-templating route include tetrapropylammonium hydroxide [22], hexadecane [26], Pluronic 
F127 [27] and polystyrene latex [28]. Soft-templating method has been proved to be a simple 
and effective synthesis approach of hollow MSNs. However, hollow MSNs obtained through 
this method tend to collapse during the surfactant removing process. Moreover, it is hard to 
completely remove the cave template through solvent extraction and this in turn will lead to 
severe side effects when hollow MSNs are used to deliver drugs to human [23].  
 
  
Figure 3 Schematic illustration of the formation process of HMSs [25] 
 
Another strategy for the synthesising of HMSNs relies on employing some solid particles like 
silica and hematite as hard templates to build a hollow interior cave after template removal 
process. This fabrication route is made up of four steps: (a) the formation of solid cave 
templates; (b) core template dispersion. Sometimes functionalization is needed to ensure core 
surfactants coat the cave templates favourably; (c) silica mesoporous shell generation; and (d) 
the removal of solid cave. The diameter of the spheres and the caves can be easily tuned by 
changing the solid core size. Zhang et al [29] prepared hollow MSNs with tunable shell porosity 
by transforming solid silica particles to hollow structure in NaBH4 solution. Other hard 
templates being used to create hollow structures are nanospheres of carbon, metals and metal 
oxides [30]. In general, the challenge of this approach is to fabricate hollow MSNs with small 
diameters (under 100nm). 
 
Recently, the fabrication of hollow MSNs through select-etching method was developed. 
Hollow interiors are generated by making use of etching agents to etch the inner cores. This 
strategy is based on the structural differences or compositional differences between the core 
and shell structures [31]. Chen et al [19, 31] prepared hollow/rattle-type MSNs by using sodium 
carbonate solution to etch solid silica nanoparticles, resulting in the building of a hollow cave 
in the middle (Figure 4).  Hollow MSNs were also synthesized with three different pore sizes 
by a structural difference based selective etching method [32]. In this work, hollow MSNs 
exhibited the function of controlling drug release rate which was achieved by changing the 
pore sizes. Similarly, a surface protected approach was developed [33] to prepare hollow MSNs 
in which the interior of solid silica spheres was selectively etched by NaOH while their near 
surface layer was protected by poly (vinyl pyrrolidone). 
 
 
 
Figure 4 Formation (left) and microscopic structure (right) of hollow/rattle-type MSNs [31] 
 
  
3. Modification of MSNs for smart delivery 
 
 
Figure 5 Introduction of functional groups in different regions of MSN, (a) at the external 
surface, (b) at the pore entrances, or (c) within the walls [7]. 
 
After the preparation of MSNs, it is essential that these as synthesized nanocarriers possess 
designed properties for specific drug delivery systems, such as high cellular uptake, effective 
cell internalization, higher binding affinity with targeting molecules. In this regard, 
modification of MSNs is always needed to make MSNs smart carriers for targeting.  
 
As there are many hydroxyl groups existing on the surfaces, MSNs can be modified very easily 
in different regions, including pore walls, the interior/exterior surfaces and the pore entrance 
(Figure 5). The introduction of functional groups results in more versatile MSNs. For example, 
creating hydrophobic and hydrophilic surfaces, and positively and negatively charged surfaces, 
improving biocompatibility and targeting functions, and regulating drug release rates can be 
attained by the functionalization of MSNs. He and colleagues [34] changed the surface charge 
of SBA-15-structured mesoporous silica nanoparticles from -31.1 mV to 29.6 mV by grafting 
rhodamine B onto the surfaces. Owning to electrostatic attraction, the resulting positively 
charged MSNs showed an outstanding sustained-release property for a negatively charged drug. 
The surface of MSNs can be modified with trihydroxysilylpropyl methylphosphonate (THMP) 
to improve their dispersion [35] as the introduction of THMP on the surface of MSNs increased 
the electrostatic repulsion between the MSNs and therefore decreased the aggregation. 
 
Methods used for surface modification of MSNs include post synthesis grafting, molecular 
imprinting, and organosiloxane/siloxane co-condensation. Some functional groups have been 
widely introduced onto the surface of MSNs through one or more of these methods.  
 3.1 Surface Modification 
 
Due to the quantum effect of nanosilica, the surface of nanoparticles is covered by tremendous 
number of active hydroxyl groups. These groups provide potential platform to graft 
multifunctional polymers onto the surface of external nanoparticles and interior channels. The 
surface modification creates hydrophobic or hydrophilic surfaces and introduces a unique 
functional group (C=C, –COOH, or –NH2) onto the surface. The multifunctional grafting 
focuses on improving biocompatibility, and protecting and controlling the release of guest 
molecules. The surface modification provides MSNs with multifunction that can facilitate the 
delivery of biomolecules into cells. 
 
Silane coupling agents are the most commonly used chemicals in surface modification of silica 
based materials. Reacting with the hydroxyl groups on the surface, the coupling agents can 
build a bridge that connects organic materials. They also provide a variety of functional groups, 
such as amine groups, double carbon bonds and epoxy groups (Figure 6). This coupling 
characteristic as a pre-treatment has been widely utilised to provide the foundation for further 
modification [36-40]. Also, the functional groups brought by silane modification can introduce 
different surface properties, such as surface charges and hydrophilicity, which can potentially 
tune both the capacity of drug loading and the releasing duration [37]. In addition, coupling 
agents are chemically incorporated on the surface of MSNs so that a successful grafting group 
is tolerant of physical treatment such as washing, dissolving and stirring. 
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Figure 6 Formulation of silane coupling agents. 
 
3.2 Stimuli-responsive Modification 
 
  
Figure 7 (A) Schematic indication of assembled gold gatekeepers; (B) TEM images of plain 
MSNs and (C) MSNs with gold nanoparticle gatekeepers at the entrance [41]. Gold 
nanoparticles are indicated by white arrows in (C). 
 
Various conditions, such as pH value, temperature, magnetism and light, can be used as triggers 
to release chemicals into the environment [42]. A number of stimuli-responsive protectors have 
been developed to achieve controlled release. Due to specific porous structure of MSNs, most 
stimuli-responsive functionalization happens through gatekeepers at the entrance of the 
channels (namely mesopores). Gold (Au) nanoparticles are the most commonly used medium 
for this purpose. Au nanoparticles and MSNs can be connected with pH sensitive polymers [41, 
43]. In neutral conditions, guest molecules are blocked in the channels of MSNs. The results 
show that the gold gatekeepers are located at the end of mesopore channels (Figure 7 C) under 
electron microscope after assembly onto the raw MSNs (Figure 7 B). When the surrounding 
pH becomes acidic, the hydrolysis of acetal groups allows the gates blocked by gold to be open, 
leading to the release of entrapped molecules (Figure 7 A). For the redox-responsive release, 
cadmium sulfide nanoparticles (CdS) nanoparticles and organic molecules have been 
implemented to protect guest molecules in MSNs, based on the theory of conditional 
stimulation [44-46]. The light mediated release of loaded cargos is related to the light sensitive 
materials, such as gold nanorods [47, 48] and rare element particles [49], which can maintain 
the loaded molecules in mesopores and responsively release them with an external light source. 
However, because the main compositions of these gatekeepers are heavy metals that have 
adverse effects on plant cells and tissues after breaking away from MSNs, the potential use of 
these types of nano gatekeepers must be carefully examined. A recent study suggested that 
short-chain molecules can be used as redox-responsive gatekeepers to control the release of a 
plant hormone – salicylic acid (SA) [50]. The toxicity issue brought by metal gatekeepers can 
be minimised by this new gatekeeper system. The short-chain molecules were grafted on MSNs 
with disulfide bonds, and glutathione (GSH), an endogeneous protein, can trigger the cleavage 
of disulfide bonds, which induce the release of loaded biomolecules (Figure 8). The results 
from in vitro release showed the GSH concentration dependent release patterns. This GSH 
mediated release of SA has also been tested in vivo, which indicates the continuous expression 
of pathogen resistant gene (PR-1) for up to 7 days compared to the short expression of PR-1 
with bare SA treatment. 
 
  
Figure 8 (A) Schematic of functionalization of MSNs with thiol (-SH) groups and assembly of 
gatekeepers on to SA loaded MSNs. (B) Cumulative amount of SA released from short-chain 
molecule capped MSNs under different GSH concentration. (C) Housekeeping gene actin and 
defence gene (PR-1) expression in Arabidopsis with MSN, SA and SA loaded and capped 
MSNs (SA@MSN-SS-C10) treatment on day 3, 5 and 7. M is HyperLadderTM IV (Bioline) and 
-Ve is the blank channel. Actin is at the top row and PR-1 is at the bottom row. 
 
3.3 Biocompatible polymeric coating 
 
Biocompatible polymeric coatings can potentially enhance the permeability and retention, due 
to the improvement in biocompatibility. PEGylation is a representative technique that can 
achieve homogeneous particle dispersion and particularly reinforce the permeability of MSNs 
across the cell membrane. Several biocompatible materials have been used to coat onto the 
surface of MSNs, including PEG (poly(ethylene glycol)) [51] and TEG (triethylene glycol) 
[43]. After MSNs are PEGylated, it is obvious from the confocal microscopy images (Figure 
9) that the modified MSNs have more chance to be internalised into cells [51].  
 
 
 
Figure 9 Distribution of hollow sphere mesoporous silica (HSMS) in Hela cells. (a) HSMS 
with fluorescent agents; (b) HSMS-PEG with fluorescent agents [51]. The cell nuclei are in 
blue and nanoparticles are in red. 
 
In addition to the enhancement in permeability, the release kinetics of loaded molecules can be 
manipulated by the polymeric coatings with different thicknesses. Niu et al. [52] prepared core-
shell mesoporous silica spheres with controllable shells with a thickness of 5 nm, 25 nm and 
60 nm, respectively. The shell is also formed by mesoporous silica and can have different pore 
size. Due to the size gradient of mesopores, chemicals loaded inside can be gradually released 
according to the thickness of the shell. The results showed that the thicker the shell coatings 
are, the longer the release takes (Figure 10). This methodology indicates another prospect of 
the controlled drug delivery systems. 
 
 
 
Figure 10 Different shells with different release rate of drugs [52]. The TEM images (left three 
figures) show the core shell structure of MSNs, and the release kinetics (right graph) show the 
difference of release duration. 
 
  
4 Targeted drug and gene delivery 
 
4.1 Accumulation of MSNs in tumour via EPR effect 
 
Various methods have been used to fabricate MSNs with different features that are favourable 
for drug loading, release and intracellular delivery. Most of them were designed to achieve 
passive tumour targeting via enhanced permeability and retention (EPR) effect as this is the 
principle mechanism for nanoparticles to accumulate in tumour site after intravenous injection 
[53]. With more stable structure compared to biodegradable nanocarriers, MSNs are supposed 
to maintain their formation in the circulation for longer time and protect the cargoes from 
premature release. The study of biodistribution of MSNs in live animals should be necessary 
before the drug loaded MSNs can be used in human body and the data from this study will be 
invaluable to improve the effect of MSNs on targeted drug delivery.  
 
Many researchers have studied the biodistribution of MSNs in tumour bearing mice to 
investigate their tumour accumulation by “EPR” effect. Lu et al. prepared folic acid (FA) 
grafted MSNs with particle size of 100-130 nm and investigated the biodistritubtion in nude 
mice bearing subcutaneous MCF-7 xenografts [6]. The accumulation of MSNs with or without 
folic acid in the tumours can be detected by the fluorescent labelling on the particles 4 and 24 
h post injection. The quantitative measurement of MSNs and FA-MSNs in tissues was achieved 
by detecting silica amount 4, 24 and 48 hours post injection using ICP-MS. The tumours in 
mice treated with MSNs were found to have higher silica concentration than other organs, 
which can be attributed to the passive tumour targeting “EPR” effect. The active targeting 
effect of folic acid on MSNs was demonstrated by the enhanced FA-MSNs accumulation in 
tumour compared to MSNs. Similar result can be seen in the study conducted by Mamaeva and 
co-worker [54] that folate-tagged MSNs remained in tumour with longer time than MSNs 
without folate. This phenomenon can be explained by the higher cellular uptake of folate-
tagged MSNs compared to MSNs without folate because of the targeting capability of folic 
acid. As the MSNs can be preferably taken in tumour xenograft, they should be able to bring 
anti-cancer drugs in tumour cells. This hypothesis can be demonstrated by detecting the drug 
concentration in the tumours after intravenous injection of drug loaded MSNs. Similarly DOX 
was loaded onto MSNs to overcome multidrug resistance in cancer cells in vitro and in vivo 
[55]. The biodistribution of DOX was investigated after intravenous injection of DOX-MSNs. 
The results showed that the mice treated with DOX-MSNs had higher DOX concentration in 
tumour than that of mice treated with free DOX. This study confirmed the different 
mechanisms of DOX in MSNs and free DOX accumulating in tumours. 
 
Based on these progresses on understanding the biodistribution of MSNs in vivo, other efforts 
have been made to optimise the targeting effect of MSNs by changing their properties. With 
smaller size and modified surface with polymers, particle opsonisation of MSNs can be reduced 
with better monodispersion and tumour accumulation. After intravenous injection of 50 nm 
doxorubicin-loaded MSNs grafted with polyethyleneimine-polyethylene glycol copolymer in 
tumour bearing nude mice, around 12% of injected MSNs can be detected in tumour site with 
high internalization of DOX in KB-31 cells. At the same time, the anti-tumour effect of DOX 
loaded in MSNs was enhanced with less systematic side effect as compared with free DOX 
[56]. Chen et al. investigated the biodistribution of TRC105 (an antibody binds to CD105) 
conjugated HMSN in the mice with breast cancer and found the tumour accumulation of 
injected particles in mice treated with TRC105-HMSNs was 10% ID/g, which was 3 times 
higher than that in mice treated with HMSNs without TRC105 [57]. With their superior tumour 
accumulation due to passive EPR effect and active targeting agent grafted on the surface, MSNs 
have also been explored as in vivo PET imaging agent, which can be achieved by labelling 
MSNs with radioactive element [58-60]. As such, MSNs tend to be explored as theranostic 
nanomedicine that acts as both imaging agent for tumour diagnosis and nanocarriers for cancer 
drug delivery. Chen et al. [61]  developed MSNs based theranostic nanoparticles for cancer 
management. Copper sulfide (CuS) nanoparticles were encapsulated in the core of MSNs as 
imaging agent owing to their near-infrared fluorescent absorption. The CuS@MSN was also 
labelled with copper-64 for biodistribution study by PET imaging. The surface of MSNs was 
modified with PEG and TRC105 for better biodistribution and active tumour targeting. The 
biodistribution study in tumour bearing mice reveal that 64Cu-CuS@MSN-TRC105 can be 
highly taken in tumour site, which makes the MSNs a promising theranostic nanomedicine for 
future cancer management [61]. 
 
From those biodistribution studies on the tumour bearing mice, the liver and spleen can be 
found to have high accumulation of MSNs. The biodistribution study of MSNs in mice without 
tumour have also revealed this phenomenon. Liu and co-workers [62] studied the silicon 
content in different organs by inductively coupled plasma-optical emission spectrometer (ICP–
OES) after intravenous injection of 80 mg/kg of MSNs in healthy mice. MSNs in liver and 
spleen can reach the peak at 24 h with 85% of the injected MSNs. The level of MSNs in liver 
and spleen decreased after 24 hours and can be detected within 4 weeks. This study suggested 
that MSNs have long circulation time in the body and can be excreted from reticuloendothelial 
system (RES) in liver and spleen, in which the MSNs will be taken by macrophages. PEG was 
often grafted on the surface of MSNs to improve their dispersity and performance in vivo, as 
demonstrated by He et al [63] that the PEGylated MSNs were able to escape RES and tended 
to have longer blood-circulation lifetime with slower renal clearance rate. The effects of 
different factors such as shape [64], size [56, 63], charge [65, 66], and porosity [67] on MSNs 
biodistribution have also been investigated. All these approaches were intended to increase the 
circulation time of MSNs in the body and decrease their accumulation in the RES so that the 
MSNs would have a higher chance to accumulate in tumour site by EPR effect. 
 
4.2 Internalization of MSNs in cancer cells 
 
When the MSNs reach the tumour site through circulation, they are supposed to deliver anti-
cancer drugs in tumour cells. Ideal MSNs should be able to enter target cells and release drugs 
intracellularly. The most important barrier that blocks MSNs from uptake by target cells is the 
cell membrane. Large particles cannot penetrate the cell membrane; they are internalized into 
cells mainly by endocytosis [68]. Endocytosis is a process in which particles first interact with 
the cell surface, become wrapped by the cell membrane and are invaginated, then the vesicles 
form to enclose the particles and transfer them to endosomes and lysosomes [69]. There are 
several different types of endocytosis, such as phagocytosis, macropinocytosis, clathrin-
mediated, caveline dependent and receptor-mediated endocytosis [70]. Slowing and co-
workers [71] studied the endocytosis mechanism of MSNs capped with poly (amidoamine) 
(PAMAM) dendrimer (PAMAM-MSNs) in Hela cells. Using specific endocytic trafficking 
inhibitors, they demonstrated that the uptake of MSNs occurred via a clathrin-dependent 
endocytosis mechanism. The endocytic process of MSNs could also be monitored using 
differential interference contrast microscopy and different steps related to endocytosis 
including Brownian motion in the cell, being trapped on the cell membrane and formation of 
vesicle in cytoplasm had been observed during the process of MSNs internalization in human 
lung cancer cells [72]. The endocytosis of MSNs in MDA-MB-468 cells was confirmed as the 
MSNs were observed to be co-localized with lysosomes [73]. Hollow MSNs could enter cells 
in a similar endocytic mechanism [74]. 
 
The particle size of MSNs may affect their internalization in cells. MSNs with different sizes 
(30, 50, 110, 170, and 280 nm) were fabricated and the influence of particle size on cellular 
uptake in Hela cells was investigated [75]. They found that MSNs of 50 nm are the most 
favourable size for efficient internalization in Hela cells. To examine the internalization of 
MSNs in MC3T3-E1 cells, MSNs with particle size ranging from 55 nm to 440 nm were 
fabricated . In vitro result suggested that MSNs with particle size around 100 nm had highest 
cellular uptake rate [76]. Ekkapongpisit et al. found that the MSNs with the particle size of 10 
nm and 50 nm were both internalized in ovarian cancer cells via caveolae-mediated endocytosis. 
However, the 50 nm MSNs was observed to be resided within lysosomes while the 10 nm ones 
can escape from endo-lysosomes and enter the cytoplasm [77]. Thus the MSNs of smaller size 
may have better performance on intracellular delivery of drugs to cytoplasm. The “ultrasmall” 
small hollow MSNs with a size of 24.7 nm have been demonstrated to have better endocytosis 
properties in HeLa cells compared to conventional and larger mesoporous silica nanoparticles 
[78].  
 
There are many other factors that can also influence the uptake of MSNs in cells including the 
surface charge, shape and structure. Since the cell membrane harbours negative charge on the 
surface, it is believed that MSNs with a positive charge can be internalized more efficiently 
than MSNs with a negative charge. The effect of the surface charge on MSNs cellular uptake 
in hMSCs and 3T3-L1 cells was investigated [79] and it was found that positively charged 
MSNs have a higher internalization rate in 3T3-L1 cells compared to MSNs with negative 
charge. However this was not found in hMSCs cells, suggesting that the effect of charge could 
be cell dependent. The study from Ekkapongpisit et al. revealed that the MSNs with positive 
charge had higher cellular uptake rate in in ovarian cancer than MSNs with negative charge 
[77]. Another study reported MSNs grafted with cationic liposomes Lipofectamine 2000 had 
higher cellular uptake rate than that of naked MSNs with negative surface charge, which 
confirmed the charge effect on the endocytosis of MSNs [80].  
 
The shape of MSNs can also affect their internalization rate in cells. Trewyn et al. investigated 
cellular uptake of both spherical and tube-shaped MSNs in human fibroblast cells [81]. The 
endocytic rate of spherical MSNs was significantly higher than that of rod-like MSNs, which 
could be explained by the theory of “wrapping time” that it may take longer time to wrap a rod 
shape particle than a sphere because of the larger surface area [82]. However, the study on the 
effect of shape on MSNs cellular uptake by Huang et al. obtained an opposite result: MSNs 
with largest aspect ratio exhibited highest cellular uptake rate [83]. A different mechanism was 
introduced to interpret the data: rod shape MSNs have larger contact area with the cell 
membrane than spherical ones which is more favourable for cellular uptake. More studies 
should be conducted to confirm the shape effect on MSNs cellular uptake in the future. 
 
The enhanced uptake of MSNs can be achieved by surface modification with targeting 
molecules [84]. Recently, MSNs have been conjugated with various ligands recognizable by 
receptors on the cell membrane to achieve active targeted drug delivery via receptor-mediated 
endocytosis. Folic acid have been frequently used as targeting ligand for various nanocarriers 
due to the overexpression of folate receptor on most cancer cells. Since it was reported that 
folic acid on polyethylene imine (PEI) coated MSNs could facilitate their cellular uptake via a 
receptor-mediated endocytosis [85], folic acid has been grafted on MSNs as effective targeting 
agent to deliver various therapeutic cargoes into different cancer cells [86-90]. Many other 
studies attached hyaluronic acid on the MSNs surface to target CD44 overexpressed cancer 
cells [91-95].  
 
Epidermal growth factor receptor (EGFR) have been found overexpressed in most cancer cells 
and could be explored as biomarkers for active targeting of nanocarriers. It was found that 
epidermal growth factor receptor antibody (EGFRAb) conjugated MSNs had superior cellular 
uptake rate in lung cancer cells compared to normal lung cells due to the overexpression of 
EGFR in lung cancer cells that can facilitate the receptor-mediated endocytosis of EGFRAb-
MSNs [96]. Recently, EGF was grafted on the surface of hollow MSNs to target EGFR on 
colorectal cancer cells. The amount of EGF on the surface of HMSNs can be controlled and 
determined by time of flight secondary ion mass spectrometry (ToF-SIMS) [97] and specific 
internalization of HMSNs in colorectal cancer cells can be achieved via EGF-EGFR mediated 
endocytosis with high 5-FU intracellular release to overcome drug resistance [98, 99].   
 
4.3 Delivery of siRNA by MSNs for gene therapy 
 
Since the double-stranded RNA (dsRNA) was first demonstrated to have RNA interference 
(RNAi) effect in 1998 by Fire and his colleges [100], this technology has been widely used to 
knock down pathological gene expression for treatment. After internalized into cells, dsRNA 
can be recognized by the enzyme Dicer and cleaved to short interfering RNA (siRNA). siRNA 
is then loaded into RNA-induced silencing complex (RISC), the double strand of RNA will be 
separated in RISC, and the guide strand that is complementary to the mRNA sequence can be 
hybridized to mRNA and cause the gene silencing by targeted mRNA cleavage [101]. Using 
this technology, gene therapy that silences certain genes can be promising for diseases such as 
cancer in which upregulation of certain gene expression can be identified. As for drug 
resistance in cancer, there are various mechanisms involved including pump and non-pump 
resistance. Some transmembrane proteins have been identified such as P-glycoprotein (Pgp) 
which can act as drug efflux pump [102]. Besides Pgp, other factors that influence apoptosis, 
DNA damage repair or drug metabolism can also play an important role in drug resistance. 
Furthermore, due to different drugs being used in cancer therapy, the mechanism of drug 
resistance may be different. After identification of specific genes or proteins that regulate drug 
resistance, siRNA can be used to knock down those genes to retain drug sensitivity. With the 
stable porous structure, tuneable size, high loading efficiency and large surface area for 
chemical modification, MSNs can be a suitable vector for co-delivery of anti-tumour drugs and 
siRNA to overcome drug resistance. 
 
Due to their mesoporous structure, the MSNs have large surface area that can be grafted with 
various functional groups that are favourable for drug and siRNA loading. Taking advantage 
of the negative charge on siRNA, MSNs can be functionalized with positively charged links to 
attract siRNA by charge effect. Polyethyleneimine (PEI) polymers were grafted on the MSNs 
to generate a cationic surface to which siRNA can be attached. The effective siRNA delivery 
by PEI functionalized MSNs was demonstrated by the successful gene knocking down of GFP 
expression [103]. Then the PEI-MSNs were used for co-delivery of doxorubicin (Dox) and P-
glycoprotein (Pgp) siRNA to KB-V1 cells for overcoming the drug efflux pump mediated 
multiple drug resistance (MDR). The effective delivery of siRNA by PEI-MSNs can silence 
the Pgp expression in KB-V1 cells and restore the sensitivity of cells to Dox [104]. This system 
was then functionalized with PEG for in vivo tumour siRNA delivery via EPR effect. The 
results demonstrated that siRNA and Dox co-delivered with MSNs can cause effective tumour 
biodistribution and lead to synergistic inhibition of tumour growth in vivo with significant Pgp 
gene knockdown [105]. PEI has been frequently used in MSNs based siRNA delivery system 
as effective coating for siRNA attachment [106-111]. 
 
However, the cytotoxicity of PEI may limit its application in vivo. Chen and co-workers 
modified MSNs with cationic generation 2 (G2) amine-terminated polyamidoamine (PAMAM) 
to absorb B-cell lymphoma 2 (Bcl-2) siRNA and co-deliver Dox into multidrug resistant 
A2780/AD human ovarian cancer cells. This siRNA co-delivery system was demonstrated to 
be capable of silencing Bcl-2 mRNA and enhancing cytotoxicity of Dox [112]. Other types of 
cationic polymers such as poly(2-(diethylamino)ethylmethacrylate) (PDEAEMA) [113], poly-
L-lysine (PLL) [114] and poly(2-(dimethylamino)ethylmethacrylate) (PDMAEMA) [113] 
have also been used in MSNs based siRNA delivery system with effective siRNA loading and 
intracellular delivery to cause gene silence.  
 
In most of the above studies, siRNA were attached to the cationic polymers on the MSNs 
surface through electrostatic interaction. Thus the amount of siRNA loaded on MSNs may be 
limited if the space within the mesopores of MSNs cannot be utilized. Li and co-workers [115] 
packaged Bcl-2 siRNA into the mesopores of magnetic MSNs under a strong dehydrated 
solution conditions. The siRNA loaded MSNs were then grafted with PEI to protect siRNA 
from premature release. This siRNA loaded MSNs can be internalized into cancer cells and 
release siRNA to silence Bcl-2 genes. By grafting a fusogenic peptide (KALA) on the surface 
of MSNs, the active targeting effect of this siRNA delivery system was achieved [109]. 
Furthermore, this siRNA delivery system was functionalized with PEG and systematically 
administrated in tumour bearing mice with effective vascular endothelial growth factor (VEGF) 
gene silencing in vivo [116, 117]. Another effective way of increasing the siRNA loading in 
mesopores that have been demonstrated is to expand the pore size and pore volume for more 
siRNA to enter the pores. MSNs with large cubic pores (13.4 nm) functionalized with poly-L-
lysine (PLL) were prepared for gene delivery applications; this system was able to carry siRNA 
with high efficiency and cause specific gene silence [114]. Another study demonstrated that 
MSNs with ultra large pores (23 nm) was able to load much more siRNA as compared with 
MSNs with regular pores (2.1 nm). The gene silencing effect of siRNA loaded ultra large pore 
MSNs was further confirmed in vitro and in vivo [118]. With large cavity in the core, hollow 
MSNs were supposed to have more space for siRNA loading compared to transitional MSNs. 
Chen et al. prepared hollow MSNs and further expanded the pore sizes from 3.2 nm to larger 
than 10 nm using a surfactant-directing alkaline-etching (SDAE) strategy. The hollow MSNs 
with large pore size have been demonstrated with higher siRNA-loading capabilities compared 
to HMSNs with small pores and effective siRNA intracellular transfection in vitro [106]. 
 
In light of the versatility of MSNs on drug delivery and release, some of the features such as 
active targeting and stimuli-responsive release can be also incorporated in MSNs based siRNA 
delivery system. Ashley et al. developed mesoporous silica nanoparticle supported lipid 
bilayers for siRNA delivery with multifunction. The MSNs core was loaded with siRNA and 
then grafted with liposomes on the outer surface. With the supported liposome bilayers on the 
surface, various functional molecules including PEG, targeting peptides and endosomolytic 
peptides can be attached. These so called “protocells” were able to specifically deliver siRNA 
into target cells and cause effective gene knock down on protein level [119]. Furthermore, the 
controlled intracellular release of siRNA from MSNs can be a promising way to protect siRNA 
from premature release in the physiological environment. Taratula and co-workers developed 
a MSNs based siRNA delivery system for inhalation treatment of lung cancer. siRNA targeting 
Pgp and Bcl-2 were attached to the surface of MSNs through disulphide bond which can be 
cleaved by redox in the cytoplasm [120]. Similar mechanism of siRNA released from MSNs 
that relied on disulphide bond cleavage was designed by Ma et al [121]. However, the siRNA 
was not connected with MSNs directly but attached to adamantane and ethylenediamine-
modified β-cyclodextrin that were grafted on MSNs by disulphide bond to protect encapsulated 
Dox in pores from premature release. The intracellular acidic environment has also been 
explored as a trigger to activate the release of siRNA from MSNs [110]. 
 
5 Characterization and analysis via computer aided strategies  
 
5.1 Determination of the surface area, pore geometry and pore size of MSNs 
 
Large surface area, controllable pore geometry and pore size are advantageous properties of 
MSNs as drug carriers for targeted delivery. Depending on the physical characteristics of MSNs, 
several models were used to determine the surface area of MSNs, like Brunauer-Emmett-Teller 
(BET) method [122-127], Langmuir calculation and t-Plot calculation [128, 129]. The BET 
calculation obtains the sample surface area value by determining the monolayer volume of 
adsorbed gas from the isotherm data. The Langmuir calculation determines the surface area of 
a sample by relating the surface area to the volume of gas adsorbed as a monolayer. The t-Plot 
calculation allows quantitative analysis of the area and total volume ascribed to micropores. 
Matrix area, the area external to micropores, is directly determined by this method. Thus, t-
Plot calculation often proves to be a valuable way of characterizing MSNs with microporosity 
and mesoporosity [130, 131]. Software such as MicroActive is widely used for these 
calculations.  
 
According to the types of pores that define the networks, MSNs are divided into several types, 
such as Mobil Crystalline Materials (MCM-41) and Santa Barbara Amorphous type (SBA-16) 
[132]. Owning to different pore structure, the way of gas evaporation differs from one another, 
which results in the change in shape of the hysteresis loops on nitrogen adsorption-desorption 
isotherms (Figure 11) [133-135]. Sarkisov and Monson [134] studied the gas adsorption and 
desorption in pores with different pore geometries using computer graphics visualization. It 
was found that for the ink bottle geometry the large pore can empty during desorption even 
while the small pore remains filled with fluid. 
 
The pore size of MSNs can be investigated by a suite of characterization techniques, such as 
Brunauer-Emmett-Teller/Barrett-Joyner-Halenda (BET/BJH), X-ray diffraction (XRD) and 
Positron Annihilation Lifetime Spectroscopy (PALS). These techniques provide different 
information whilst are complementary to each other. Morishige and Tateishi calculated the pore 
size of the ordered mesoporous MCM-41 and SBA-15 and found that a macroscopic 
thermodynamic approach based on Broekhoff-de Boer equations was in fair agreement with 
the experimental relation in their study [136]. 
  
 
Figure 11 Effect of pore geometry on shapes of hysteresis loop. H1-H4: types of hysteresis 
loops  
 
5.2 drug delivery kinetics 
 
In the attempt to investigate the release kinetics of MSNs based drug delivery systems, 
equations and models [137, 138] were developed to describe the release behavior of these 
systems. For example, Eq. 1 was introduced by Ritger and Peppas for description of solute 
release from non-swellable and swellable devices in controlled release systems [139, 140],  
𝑴𝒕
𝑴∞
= 𝑲𝒕𝒏        (1) 
where Mt/M∞ is the accumulative release percentage of drug at time t; k is a constant and n is 
the diffusional exponent indicating the transport mechanism of the drug from their carriers. 
Table 1 lists the diffusional exponent values (n) and their corresponding drug release 
mechanism based on literature [141, 142]. Besides, Doadrio and co-workers constructed a 
molecular model to investigate the release behaviour of Chicago Sky Blue 6B from SBA-15 
by molecular modelling calculations [143]. According to this model, the controlled release 
mechanism of SBA-15 functionalized with 3-aminopropyl-triethoxy-silane was fully explained. 
Similarly, the drug dissolution kinetics from ordered mesoporous silica MCM-41 and SBA-15 
were modelled by Murzin and co-workers [144]. In their study, a simple model with two 
adjustable parameters was built to explain the Sigmoidal Behaviour of drug dissolution. Several 
models have been introduced to interpret the release kinetics of cephalosporin from 
functionalized MCM-41 [145]. The correlations between the delivery rate and the surface 
properties of MCM-41 were successfully reflected by model parameters.   
 
Table 1 Values of diffusional exponent and corresponding drug release mechanism 
 
  
Diffusional exponent, n  
Drug release 
mechanism 
Thin film Cylindrical 
samples 
Spherical samples 
 
< 0.50 
 
< 0.45 
 
< 0.43 
Quasi-Fickian 
diffusion 
0.50 0.45 0.43 Fickian diffusion 
 
0.50< n < 1.00 
 
0.45 < n < 1.00 
 
0.43 < n < 1.00 
Non-Fickian 
diffusion 
(Anomalous 
transport) 
1.00 1.00 1.00 Zero-order release 
6 Perspectives and concluding remarks 
 
The studies reported in this review established MSNs as a smart drug carrier that effectively 
transports drug/genes to the targeted cell population, but challenges remain for these MSNs 
based drug delivery systems to be further advanced and available for clinical purposes. For 
example, although modifications have made MSNs more versatile for applications, they also 
have disadvantages to be exploited as drug carriers. Firstly, if not well controlled, surface 
modifications of MSNs would cause structure collapse [26]. Further, the introduction of 
chemical groups on the surface of MSNs may create additional toxicity which makes MSNs 
unsuitable as carriers for drug delivery systems. Moreover, in many cases, it is difficult to 
couple several functional groups with sufficient concentration, since the number of active 
attachment sites on the particle surface is limited. In addition, each functionalization step might 
negatively affect the suspension stability of the particulate system, depending on the 
physicochemical properties of the added function. Therefore, all these issues should be 
considered when a drug delivery system is engineered based on modified MSNs and the 
development of effective methods to deal with these problems is of great importance.  
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